Incyte Corporation (FRA:ICY)

Market Cap	16.54B +21.9%
Revenue (ttm)	4.10B +18.1%
Net Income	1.01B +3,559.2%
EPS	5.03 +3,878.0%
Shares Out	n/a
PE Ratio	16.32
Forward PE	12.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46
Average Volume	88
Open	84.16
Previous Close	83.38
Day's Range	84.16 - 84.96
52-Week Range	49.00 - 95.56
Beta	n/a
RSI	42.85
Earnings Date	Feb 10, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ICY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD